Melinta Therapeutics Inc (MLNT) - Financial and Strategic SWOT Analysis Review
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Melinta Therapeutics Inc (MLNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of the various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin in Phase 3 clinical trials for the treatment of serious community-acquired bacterial pneumonia (CABP) and and radezolid in Phase 2 clinical trials for dermatological diseases. Melintas products and pipeline candidates are built on ribosome platform licensed from Yale University. The company distributes its products through partnership with Menarini Group; and Eurofarma Laboratorios. Melinta is headquartered at New Haven, Connecticut, the US.
Melinta Therapeutics Inc Key Recent Developments
May 09,2019: Melinta Therapeutics reports first quarter 2019 financial results and provides corporate update
Mar 13,2019: Melinta Therapeutics reports fourth quarter and full-year 2018 financial results
Feb 25,2019: Melinta Therapeutics announces closing of initial $75 Million Vatera Convertible Loan Funding
Feb 04,2019: Melinta Therapeutics provides corporate updates
Dec 19,2018: John H. Johnson agrees to become permanent Chief Executive Officer of Melinta Therapeutics
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of the various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin in Phase 3 clinical trials for the treatment of serious community-acquired bacterial pneumonia (CABP) and and radezolid in Phase 2 clinical trials for dermatological diseases. Melintas products and pipeline candidates are built on ribosome platform licensed from Yale University. The company distributes its products through partnership with Menarini Group; and Eurofarma Laboratorios. Melinta is headquartered at New Haven, Connecticut, the US.
Melinta Therapeutics Inc Key Recent Developments
May 09,2019: Melinta Therapeutics reports first quarter 2019 financial results and provides corporate update
Mar 13,2019: Melinta Therapeutics reports fourth quarter and full-year 2018 financial results
Feb 25,2019: Melinta Therapeutics announces closing of initial $75 Million Vatera Convertible Loan Funding
Feb 04,2019: Melinta Therapeutics provides corporate updates
Dec 19,2018: John H. Johnson agrees to become permanent Chief Executive Officer of Melinta Therapeutics
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
TABLE OF CONTENTS
Section 1 - About the Company
Melinta Therapeutics Inc - Key Facts
Melinta Therapeutics Inc - Key Employees
Melinta Therapeutics Inc - Key Employee Biographies
Melinta Therapeutics Inc - Major Products and Services
Melinta Therapeutics Inc - History
Melinta Therapeutics Inc - Company Statement
Melinta Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Melinta Therapeutics Inc - Business Description
Product Category: Baxdela
Overview
Performance
Product Category: Minocin for Injection
Overview
Performance
Product Category: Orbactiv
Overview
Performance
Product Category: Vabomere
Overview
Performance
Product Category: Contract Research
Performance
Product Category: License Revenue
Performance
Product Category: Net Product Sales
Performance
R&D Overview
Melinta Therapeutics Inc - Corporate Strategy
Melinta Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Melinta Therapeutics Inc - Strengths
Melinta Therapeutics Inc - Weaknesses
Melinta Therapeutics Inc - Opportunities
Melinta Therapeutics Inc - Threats
Melinta Therapeutics Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Melinta Therapeutics Inc, Recent Deals Summary
Section 5 Companys Recent Developments
May 09, 2019: Melinta Therapeutics reports first quarter 2019 financial results and provides corporate update
Mar 13, 2019: Melinta Therapeutics reports fourth quarter and full-year 2018 financial results
Feb 25, 2019: Melinta Therapeutics announces closing of initial $75 Million Vatera Convertible Loan Funding
Feb 04, 2019: Melinta Therapeutics provides corporate updates
Dec 19, 2018: John H. Johnson agrees to become permanent Chief Executive Officer of Melinta Therapeutics
Dec 19, 2018: Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million
Nov 07, 2018: Melinta Therapeutics reports third quarter 2018 financial results
Oct 31, 2018: Melinta Therapeutics announces appointment of Bruce L. Downey to Board of Directors
Oct 22, 2018: Melinta Therapeutics appoints John H. Johnson as Interim Chief Executive Officer
Sep 18, 2018: Melinta Therapeutics appoints Peter Milligan as Chief Financial Officer
Section 6 Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer
List Of Tables
Melinta Therapeutics Inc, Key Facts
Melinta Therapeutics Inc, Key Employees
Melinta Therapeutics Inc, Key Employee Biographies
Melinta Therapeutics Inc, Major Products and Services
Melinta Therapeutics Inc, History
Melinta Therapeutics Inc, Subsidiaries
Melinta Therapeutics Inc, Key Competitors
Melinta Therapeutics Inc, Ratios based on current share price
Melinta Therapeutics Inc, Annual Ratios
Melinta Therapeutics Inc, Annual Ratios (Cont...1)
Melinta Therapeutics Inc, Interim Ratios
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Melinta Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List Of Figures
Melinta Therapeutics Inc, Performance Chart (2014 - 2018)
Melinta Therapeutics Inc, Ratio Charts
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
RELATED REPORTS
Melinta Therapeutics Inc - Strategic SWOT Analysis Review
Melinta Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information
View ReportAnika Therapeutics Inc (ANIK) - Product Pipeline Analysis, 2021 Update
Anika Therapeutics Inc (Anika) develops, manufactures, and markets therapeutic products for degenerative orthopedic diseases and traumatic conditions. It offers solutions for ortho-biologics, dermal, ophthalmic, surgical and veterinary applications. Its major
View ReportChinook Therapeutics Inc (KDNY) - Financial and Strategic SWOT Analysis Review
Chinook Therapeutics, Inc (Chinook)., formerly Aduro BioTech Inc is a clinical-stage immunotherapy company that discovers, develops and commercializes therapies for the treatment of cancer. The company develops product candidates using
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
